{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70674"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/tirzepatide\/","title":{"rendered":"\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/strong> is a 39-amino-acid dual GLP-1 and GIP receptor co-agonist peptide and the active studies molecule behind Mounjaro and Zepbound. It produces the largest body-weight and glycaemic effect of any single peptide in current published studies, with the dual-receptor profile delivering a meaningfully greater response than single GLP-1 agonists in head-to-head trials such as SURPASS-2. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly dosing. Supplied in 5\u00a0mg to 120\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2023788-19-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">4813.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS\uff0839\u30a2\u30df\u30ce\u9178\u3001GIP\u30d9\u30fc\u30b9\u306e\u9aa8\u683c\u306bAib<sup>2<\/sup>, \u3001Aib<sup>13<\/sup>, \u3001\u304a\u3088\u3073Lys<sup>20<\/sup>-C20\u8102\u80aa\u9178\u4e8c\u9178\u306e\u03b3Glu-\u03b3Glu\u30b9\u30da\u30fc\u30b5\u30fc\u3092\u4ecb\u3057\u305f\u30a2\u30b7\u30eb\u5316\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f7f\u7528\u6642\u5728\u5eab\u306f2\uff5e8\u2103\uff08\u51b7\u8535\uff09\u306b\u4fdd\u7ba1\u3002\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u221220\u2103\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u2103\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u6642\u9593\u4f7f\u7528\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/strong> is a 39-amino-acid dual incretin receptor co-agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors with comparable potency. Developed by Eli Lilly and disclosed in 2018, it was the first dual-incretin agonist to reach regulatory approval (Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023). Tirzepatide is built on the GIP peptide backbone \u2014 not the GLP-1 backbone used by semaglutide \u2014 with two \u03b1-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that resist DPP-4 cleavage and a C20 fatty diacid attached at lysine 20 via two \u03b3-glutamic acid spacers. The C20 acyl chain is one carbon longer than semaglutide&#8217;s C18, producing tighter albumin binding and a slightly different pharmacokinetic profile. Tirzepatide&#8217;s well-characterised structure has empirical formula C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub> with average molecular weight 4813.45 Da. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly subcutaneous dosing in published studies. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For broader incretin studies, see our <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> \u88fd\u54c1\u30da\u30fc\u30b8\u3002 <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 GLP-1\uff0fGIP\u53d7\u5bb9\u4f53\u30c7\u30e5\u30a2\u30eb\u30b3\u30fb\u30a2\u30b4\u30cb\u30ba\u30e0<\/h2>\n<p>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u304c\u5f93\u6765\u306e\u5358\u4e00\u30a4\u30f3\u30af\u30ec\u30c1\u30f3\u30da\u30d7\u30c1\u30c9\u3068\u7570\u306a\u308b\u70b9\u306f\u3001\u305d\u306e <strong>2\u3064\u306e\u7570\u306a\u308b\u53d7\u5bb9\u4f53\u306e\u30d0\u30e9\u30f3\u30b9\u306e\u53d6\u308c\u305f\u5171\u6d3b\u6027\u5316<\/strong>, each contributing complementary metabolic effects observed in published studies:<\/p>\n<ul>\n<li><strong>GLP-1\u53d7\u5bb9\u4f53\u6d3b\u6027\u5316 \u2014 \u6e80\u8179\u611f\u3001\u03b2\u7d30\u80de\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u3001\u80c3\u6392\u51fa<\/strong> \u2014 \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u3001\u5929\u7136GLP-1\u3068\u540c\u7b49\u306e\u89aa\u548c\u6027\u3067GLP-1\u53d7\u5bb9\u4f53\u306b\u7d50\u5408\u3057\u3001G\u03b1\u3092\u6d3b\u6027\u5316\u3057<sub>s<\/sub>-\u5171\u5f79\u578b\u30a2\u30c7\u30cb\u30ea\u30eb\u30b7\u30af\u30e9\u30fc\u30bc\u3068\u4e0b\u6d41\u306ecAMP\uff0fPKA\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u3002\u3053\u308c\u306b\u3088\u308a\u3001\u53e4\u5178\u7684\u306aGLP-1\u4f5c\u7528\u304c\u751f\u3058\u307e\u3059\uff1a\u81b5\u03b2\u7d30\u80de\u304b\u3089\u306e\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u306e\u30b0\u30eb\u30b3\u30fc\u30b9\u4f9d\u5b58\u6027\u5897\u5f37\u3001\u03b1\u7d30\u80de\u304b\u3089\u306e\u30b0\u30eb\u30ab\u30b4\u30f3\u6291\u5236\u3001\u80c3\u6392\u51fa\u9045\u5ef6\u3001\u304a\u3088\u3073\u5f13\u72b6\u6838POMC\u30cb\u30e5\u30fc\u30ed\u30f3\u3092\u4ecb\u3057\u305f\u4e2d\u67a2\u6027\u98df\u6b32\u6291\u5236\u52b9\u679c\u3002\u3053\u306e\u4f5c\u7528\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306e\u4f5c\u7528\u6a5f\u5e8f\u3068\u91cd\u8907\u3057\u307e\u3059\u3002<\/li>\n<li><strong>GIP\u53d7\u5bb9\u4f53\u6d3b\u6027\u5316 \u2014 \u8102\u80aa\u7d30\u80de\u306e\u8102\u80aa\u5206\u89e3\u3001\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u3001\u03b2\u7d30\u80de\u30b5\u30dd\u30fc\u30c8<\/strong> \u2014 The GIP component is what makes tirzepatide pharmacologically distinct. GIP receptor activation enhances insulin secretion in a glucose-dependent manner (complementary to GLP-1&#8217;s effect), but also acts on adipocytes to promote lipolysis under fasting conditions while supporting triglyceride storage in the fed state. Studies suggests GIP-receptor signaling also raises resting energy expenditure modestly and acts in CNS regions distinct from GLP-1, including the dorsomedial hypothalamus. The net effect is an additive body-weight signal beyond what GLP-1 alone produces.<\/li>\n<li><strong>\u53d7\u5bb9\u4f53\u30d0\u30e9\u30f3\u30b9\u3068\u69cb\u9020\u5fae\u8abf\u6574<\/strong> \u2014 In radioligand-binding assays, tirzepatide shows higher affinity for the GIP receptor than for the GLP-1 receptor \u2014 an unusual ratio that distinguishes it from earlier dual-agonist candidates. The asymmetry is intentional: the GIP backbone allows higher GIP-receptor potency while the engineered modifications preserve sufficient GLP-1 activity. Tirzepatide is sometimes described as &#8220;GIP-biased&#8221; in receptor pharmacology, which has implications for the differential signalling observed in study models.<\/li>\n<\/ul>\n<p>The C20 fatty diacid acyl tether at lysine 20 binds reversibly to circulating serum albumin, forming a peptide depot that protects tirzepatide from renal clearance and produces the ~120-hour plasma half-life. The double Aib substitution (positions 2 and 13) prevents DPP-4 cleavage at two distinct sites, providing redundant proteolytic protection. Together these structural features convert what would otherwise be a short-acting incretin into a once-weekly peptide. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Tirzepatide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u304a\u3088\u3073\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027<\/strong> \u2014 \u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3084\u4ed6\u306eGLP-1\u30e2\u30ce\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u306e\u76f4\u63a5\u6bd4\u8f03\u8a66\u9a13\uff08Frias et al., NEJM 2021 SURPASS-2\uff09\u3001db\/db\u30de\u30a6\u30b9\u3001ZDF\u30e9\u30c3\u30c8\u3001\u9ad8\u8102\u80aa\u98df\u9f67\u6b6f\u985e\u30e2\u30c7\u30eb\u3001HbA1c\u4ee3\u66ff\u30de\u30fc\u30ab\u30fc\u3001\u7a7a\u8179\u6642\u8840\u7cd6\u3001\u9ad8\u30a4\u30f3\u30b9\u30ea\u30f3\u6b63\u5e38\u8840\u7cd6\u30af\u30e9\u30f3\u30d7\u6cd5\u30d1\u30e9\u30e1\u30fc\u30bf\u3078\u306e\u5f71\u97ff<\/li>\n<li><strong>Body weight and adiposity studies<\/strong> \u2014 the SURMOUNT-1 trial showed ~22% body weight reduction at 15\u00a0mg weekly over 72 weeks, the largest single-peptide effect documented in clinical studies at the time; rodent DIO models, body composition (DEXA \/ MRI), respiratory exchange ratio<\/li>\n<li><strong>MASLD\/MASH\uff08\u4ee3\u8b1d\u6a5f\u80fd\u969c\u5bb3\u95a2\u9023\u809d\u75be\u60a3\uff09<\/strong> \u2014 \u809d\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u542b\u91cf\u3001ALT\/AST\u3001\u7dda\u7dad\u5316\u30b9\u30c6\u30fc\u30b8\u5206\u985e\u3001SYNERGY-NASH\u8a66\u9a13\u30c7\u30fc\u30bf\u30bb\u30c3\u30c8<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 \u8840\u5727\u3001\u8102\u8cea\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3001ApoE\u306b\u304a\u3051\u308b\u52d5\u8108\u786c\u5316\u9032\u884c\u3078\u306e\u5f71\u97ff<sup>-\/-<\/sup> \u30e2\u30c7\u30eb; SURPASS-CVOT\u5fc3\u8840\u7ba1\u30a2\u30a6\u30c8\u30ab\u30e0\u30c7\u30fc\u30bf<\/li>\n<li><strong>Sleep apnoea studies<\/strong> \u2014 \u9589\u585e\u6027\u7761\u7720\u6642\u7121\u547c\u5438\u75c7\u306e\u91cd\u75c7\u5ea6\u3001SURMOUNT-OSA\u30c7\u30fc\u30bf\u30bb\u30c3\u30c8\u306b\u304a\u3051\u308b\u7121\u547c\u5438\u4f4e\u547c\u5438\u6307\u6570<\/li>\n<li><strong>\u7cd6\u5c3f\u75c5\u6027\u814e\u75c7\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u814e\u4fdd\u8b77<\/strong> \u2014 \u30b9\u30c8\u30ec\u30d7\u30c8\u30be\u30c8\u30b7\u30f3\u8a98\u767a\u6027\u304a\u3088\u3073Akita\u30de\u30a6\u30b9\u7cd6\u5c3f\u75c5\u6027\u814e\u75be\u60a3\u306b\u304a\u3051\u308b\u30a2\u30eb\u30d6\u30df\u30f3\u5c3f\u3001\u7cf8\u7403\u4f53\u6ffe\u904e\u91cf\u3001\u30e1\u30b5\u30f3\u30ae\u30a6\u30e0\u62e1\u5927<\/li>\n<li><strong>Comparative incretin peptide studies<\/strong> \u2014 \u4e8c\u91cd\u4f5c\u52d5\u85ac vs \u5358\u4e00\u4f5c\u52d5\u85ac vs \u4e09\u91cd\u4f5c\u52d5\u85ac\u306e\u6bd4\u8f03\u306b\u304a\u3051\u308b\u30d9\u30f3\u30c1\u30de\u30fc\u30af\u3002\u8a73\u3057\u304f\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide-vs-tirzepatide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9 vs \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 \u30ac\u30a4\u30c9<\/a> \u3068 <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> \u985e\u85ac\u6bd4\u8f03\u306e\u88fd\u54c1\u30da\u30fc\u30b8\u3002<\/li>\n<\/ul>\n<p>\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u306e\u5168\u4f53\u50cf\u306b\u304a\u3051\u308b\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306e\u4f4d\u7f6e\u3065\u3051\u306b\u3064\u3044\u3066\u3001\u3088\u308a\u5e83\u3044\u6587\u8108\u306b\u3064\u3044\u3066\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> \uff08\u30c8\u30ea\u30d7\u30ebGLP-1\/GIP\/\u30b0\u30eb\u30ab\u30b4\u30f3\u4f5c\u52d5\u85ac\u3001\u6b21\u4e16\u4ee3\u306e\u6bd4\u8f03\u5bfe\u8c61\uff09\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/ozempic-vs-mounjaro\/\">\u5f53\u793e\u306eOzempic vs Mounjaro\u30ac\u30a4\u30c9<\/a>. \u3002\u5168\u88fd\u54c1\u3092\u898b\u308b <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks Tirzepatide in eleven lyophilized vial strengths covering the full dose-titration range from pilot dosing through multi-month bulk protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30d1\u30a4\u30ed\u30c3\u30c8\u6295\u4e0e\u3001\u4f4e\u7528\u91cf\u6f38\u5897\u3001\u77ed\u671f\u30b5\u30a4\u30af\u30eb<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maintenance strength, mid-titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u81e8\u5e8a\u540c\u7b49\u76ee\u6a19\u7528\u91cf\uff08\u627f\u8a8d\u3055\u308c\u305f\u6700\u5927\u30d2\u30c8\u7528\u91cf\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose arm, exploratory protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5358\u4e00\u30d0\u30a4\u30a2\u30eb\u3067\u8907\u6570\u9031\u306e\u30d7\u30ed\u30c8\u30b3\u30fc\u30eb\u3001\u4f4e\u3044\u518d\u69cb\u6210\u5bb9\u91cf<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, lower per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multi-month protocols, comparative dose-response studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose comparative arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>80 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, low per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>100\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u591a\u30b3\u30db\u30fc\u30c8\u7814\u7a76\u3001\u8907\u6570\u6708\u30d7\u30ed\u30c8\u30b3\u30eb<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>120\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum Bulk packs vial, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All eleven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful for users minimising injection volume or running extended multi-month protocols from a single vial. Because reconstituted solution is stable for ~30 days, the optimal vial size for a given protocol depends on weekly dose \u00d7 weeks-per-vial trade-off. <\/p>\n<h2>\u6bd4\u8f03 \u2014 \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 vs \u30bb\u30de\u30b0\u30eb\u30c1\u30c9 vs \u30ec\u30bf\u30c8\u30eb\u30c1\u30c9<\/h2>\n<p>Tirzepatide sits at the centre of the modern incretin-agonist studies landscape, between the single-receptor <a href=\"https:\/\/medsbase.com\/ja\/semaglutide\/\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/a> (GLP-1\u306e\u307f) \u3068\u4e09\u91cd\u53d7\u5bb9\u4f53 <a href=\"https:\/\/medsbase.com\/ja\/retatrutide\/\">Retatrutide<\/a> (GLP-1 + GIP + glucagon). Each step up the receptor ladder produces a progressively larger body-weight effect in head-to-head studies but also broader systemic signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1\uff08\u30b7\u30f3\u30b0\u30eb\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP\uff08\u30c7\u30e5\u30a2\u30eb\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + \u30b0\u30eb\u30ab\u30b4\u30f3\uff08\u4e09\u91cd\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30da\u30d7\u30c1\u30c9\u9aa8\u683c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (31\u30a2\u30df\u30ce\u9178)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP (39\u30a2\u30df\u30ce\u9178)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP\u69d8\uff0839\u30a2\u30df\u30ce\u9178\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d04165\u6642\u9593\uff08\u7d047\u65e5\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d04120\u6642\u9593\uff08\u7d045\u65e5\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d046\u65e5<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8102\u80aa\u9178\u30c6\u30b6\u30fc<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18\u30b8\u9178 + AEEA-AEEA<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20\u30b8\u9178 + \u03b3Glu-\u03b3Glu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20\u30b8\u9178 + \u03b3Glu<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53c2\u7167\u30d6\u30e9\u30f3\u30c9<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mounjaro \/ Zepbound<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u6cbb\u9a13\u85ac\uff08LY3437943\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0.25\u20132.4\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2.5\u201315\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312\u00a0mg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8a66\u9a13\u306b\u304a\u3051\u308b\u4f53\u91cd\u52b9\u679c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (STEP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~22% (SURMOUNT-1)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Phase 2)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3001\u5fc3\u8840\u7ba1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8840\u7cd6\uff0b\u4f53\u91cd\u306e\u8907\u5408\u3001MASH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u6700\u5927\u306e\u4f53\u91cd\u52b9\u679c<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The head-to-head SURPASS-2 trial (Frias et al., NEJM 2021) showed superior HbA1c and body-weight reduction with tirzepatide 15\u00a0mg vs semaglutide 1\u00a0mg over 40 weeks \u2014 one of the largest direct comparison datasets in incretin studies. For methodological detail on the dual- vs triple-agonist landscape, read <a href=\"https:\/\/medsbase.com\/ja\/retatrutide-vs-tirzepatide\/\">\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9 vs \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\uff1a\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 vs \u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8<\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/ozempic-vs-mounjaro\/\">Ozempic vs Mounjaro<\/a>. Users selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide), magnitude of effect (greater with tirzepatide and retatrutide), and the strength of available trial data (extensive for semaglutide and tirzepatide, still maturing for retatrutide). <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u3001\u77ed\u671f\u7684\u306a\u4f7f\u7528\u5728\u5eab\u3068\u3057\u3066\u3001\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u3067\u306f\u3001-20\u00b0C\u3067\u51cd\u7d50\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5\u3055\u308c\u305f\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u3001\u51b7\u8535\u3067\u6700\u592724\u304b\u6708\u9593\u3001-20\u00b0C\u3067\u6700\u592736\u304b\u6708\u9593\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306b\u5bfe\u3059\u308b\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u3092\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u6ce8\u5c04\u7528\u9759\u83cc\u6c34\u3092\u30da\u30d7\u30c1\u30c9\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u300210 mg\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u30012.0 mL\u306e\u9759\u83cc\u6c34\u30675 mg\/mL\u306e\u4f7f\u7528\u6fc3\u5ea6\u304c\u5f97\u3089\u308c\u3001U-100\u30a4\u30f3\u30b9\u30ea\u30f3\u30b7\u30ea\u30f3\u30b8\u306e10\u76ee\u76db\u308a\u304c500 mcg\u306b\u76f8\u5f53\u3057\u307e\u3059\u3002\u9759\u304b\u306b\u3086\u3063\u304f\u308a\u3068\u6df7\u305c\u3001\u2014 \u884c\u3046 <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3063\u3066\u2014 \u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30672\uff5e5\u5206\u9593\u9759\u7f6e\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u306a\u3051\u308c\u3070\u306a\u308a\u307e\u305b\u3093\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because tirzepatide is dosed once weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20134 weeks of dosing depending on target dose; a 50\u00a0mg vial supports 10\u201320 weeks at clinical-equivalent doses. <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is Tirzepatide used for in studies?<\/h3>\n<p>Tirzepatide is used in studies investigating glycaemic control, insulin sensitivity, body weight and adiposity, MASLD\/MASH liver disease, cardiovascular endpoints, sleep apnoea, and diabetic nephropathy. It is the most extensively characterised dual GLP-1\/GIP agonist and is the standard comparator arm for newer multi-agonist peptide studies. The pharmaceutical-grade tirzepatide sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved for human therapeutic use and is supplied strictly for clinical studies. <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u69cb\u9020\u7684\u306a\u9055\u3044\u306f\u3001\u53d7\u5bb9\u4f53\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3068\u30da\u30d7\u30c1\u30c9\u30d0\u30c3\u30af\u30dc\u30fc\u30f3\u306b\u3042\u308a\u307e\u3059\u3002\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f39\u30a2\u30df\u30ce\u9178\u306eGIP\u30d0\u30c3\u30af\u30dc\u30fc\u30f3\u306b\u57fa\u3065\u3044\u3066\u69cb\u7bc9\u3055\u308c\u3001GIP\u3068GLP-1\u306e\u4e21\u65b9\u306e\u53d7\u5bb9\u4f53\u3092\u5171\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306f31\u30a2\u30df\u30ce\u9178\u306eGLP-1\u30d0\u30c3\u30af\u30dc\u30fc\u30f3\u306b\u57fa\u3065\u304d\u3001GLP-1\u53d7\u5bb9\u4f53\u306e\u307f\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306eGIP\u6210\u5206\u306f\u3001GLP-1\u306e\u307f\u306e\u30da\u30d7\u30c1\u30c9\u3067\u306f\u751f\u3058\u306a\u3044\u8102\u80aa\u7d44\u7e54\u306e\u8102\u80aa\u5206\u89e3\u3068\u9069\u5ea6\u306a\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u306e\u5897\u52a0\u3092\u8ffd\u52a0\u3057\u307e\u3059\u3002\u76f4\u63a5\u6bd4\u8f03\u8a66\u9a13\uff08SURPASS-2\uff09\u3067\u306f\u3001\u30bb\u30de\u30b0\u30eb\u30c1\u30c91 mg\u306b\u5bfe\u3057\u3001\u30c1\u30eb\u30bc\u30d1\u30c1\u30c915 mg\u306f40\u9031\u9593\u306b\u308f\u305f\u308a\u512a\u308c\u305fHbA1c\u3068\u4f53\u91cd\u6e1b\u5c11\u3092\u3082\u305f\u3089\u3057\u307e\u3057\u305f\u3002 <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u3068\u3069\u3046\u9055\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u4e21\u65b9\u3068\u3082GIP\u30d9\u30fc\u30b9\u306e\u9aa8\u683c\u3067\u3059\u304c\u3001\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u306fGLP-1\u3068GIP\u306b\u52a0\u3048\u3066\u30b0\u30eb\u30ab\u30b4\u30f3\u53d7\u5bb9\u4f53\u6d3b\u6027\u3092\u8ffd\u52a0\u3057\u3066\u304a\u308a\u3001\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u306a\u308a\u307e\u3059\u3002\u8ffd\u52a0\u3055\u308c\u305f\u30b0\u30eb\u30ab\u30b4\u30f3\u6210\u5206\u306f\u3001\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb\u3068\u8102\u80aa\u7d30\u80de\u306e\u8102\u80aa\u5206\u89e3\u306b\u3055\u3089\u306b\u5bc4\u4e0e\u3057\u307e\u3059\u3002\u516c\u8868\u3055\u308c\u305f\u7b2c2\u76f8\u8a66\u9a13\u306e\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u30c7\u30fc\u30bf\u3067\u306f\u3001\u903112 mg\u6295\u4e0e\u3067\u7d0424%\u306e\u4f53\u91cd\u6e1b\u5c11\u304c\u793a\u3055\u308c\u3001SURMOUNT-1\u306b\u304a\u3051\u308b\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306e22%\u3092\u308f\u305a\u304b\u306b\u4e0a\u56de\u3063\u3066\u3044\u307e\u3059\u3002\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u3088\u308a\u6210\u719f\u3057\u305f\u8a66\u9a13\u30c7\u30fc\u30bf\u30bb\u30c3\u30c8\u3092\u6301\u3063\u3066\u3044\u307e\u3059\u304c\u3001\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u306f\u307e\u3060\u5f8c\u671f\u958b\u767a\u6bb5\u968e\u306b\u3042\u308a\u307e\u3059\u3002 <\/p>\n<h3>What is the typical Tirzepatide dose?<\/h3>\n<p>\u516c\u8868\u3055\u308c\u305f\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f\u901a\u5e38\u3001\u90312.5 mg\u304b\u3089\u958b\u59cb\u3057\u30014\u9031\u9593\u3054\u3068\u306b2.5 mg\u305a\u3064\u5897\u91cf\u3057\u3066\u90315\uff5e15 mg\u306e\u7dad\u6301\u7528\u91cf\u306b\u9054\u3059\u308b\u6f38\u5897\u30b9\u30b1\u30b8\u30e5\u30fc\u30eb\u3092\u4f7f\u7528\u3057\u307e\u3059\u30022.0 mL\u306e\u9759\u83cc\u6c34\u3067\u518d\u69cb\u6210\u3057\u305f10 mg\u30d0\u30a4\u30a2\u30eb\u306f5 mg\/mL\u3068\u306a\u308a\u3001U-100\u30b7\u30ea\u30f3\u30b8\u306e10\u76ee\u76db\u308a\u304c500 mcg\u306b\u76f8\u5f53\u3057\u307e\u3059\u3002 <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306fFDA\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>Pharmaceutical tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023), manufactured to GMP standards by Eli Lilly. <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f-20\u00b0C\u3067\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306b\u3088\u308a\u30da\u30d7\u30c1\u30c9\u304c\u5206\u89e3\u3055\u308c\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u3092\u907f\u3051\u3066\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3092\u518d\u6eb6\u89e3\u3059\u308b\u306b\u306f\u3069\u3046\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u4e0a\u8a18\u306e\u518d\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u6ce8\u5c04\u7528\u9759\u83cc\u6c34\u3092\u30d0\u30a4\u30a2\u30eb\u306e\u5185\u58c1\u306b\u6cbf\u3063\u3066\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u5f53\u3066\u306a\u3044\u3088\u3046\u306b\uff09\u52a0\u3048\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30672\uff5e5\u5206\u9593\u7f6e\u304d\u307e\u3059\u3002 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3089\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u3059\u300210 mg\u30d0\u30a4\u30a2\u30eb\u306b2.0 mL\u306e\u6eb6\u89e3\u6db2\u3092\u52a0\u3048\u305f\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f5 mg\/mL\u3067\u3059\u3002 <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries Tirzepatide in eleven lyophilized vial strengths: 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, 60\u00a0mg, 80\u00a0mg, 100\u00a0mg, and 120\u00a0mg. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306e\u534a\u6e1b\u671f\u306f\u3069\u306e\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306e\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f\u306f\u3001\u76ae\u4e0b\u6295\u4e0e\u5f8c\u7d04120\u6642\u9593\uff08\u7d045\u65e5\uff09\u3067\u3059\u3002\u3053\u306e\u534a\u6e1b\u671f\u306f\u3001\u30ea\u30b8\u30f320\u4f4d\u306eC20\u8102\u80aa\u9178\u4e8c\u9178\u30c6\u30b6\u30fc\u3092\u4ecb\u3057\u305f\u5faa\u74b0\u8840\u6e05\u30a2\u30eb\u30d6\u30df\u30f3\u3078\u306e\u53ef\u9006\u7684\u7d50\u5408\u306b\u3088\u308a\u9054\u6210\u3055\u308c\u3001\u30da\u30d7\u30c1\u30c9\u3092\u814e\u30af\u30ea\u30a2\u30e9\u30f3\u30b9\u304b\u3089\u4fdd\u8b77\u3057\u307e\u3059\u3002DPP-4\u5207\u65ad\u3092\u963b\u5bb3\u3059\u308b\u4e8c\u91cd\u306eAib\u7f6e\u63db\uff082\u4f4d\u304a\u3088\u307313\u4f4d\uff09\u3068\u7d44\u307f\u5408\u308f\u305b\u308b\u3053\u3068\u3067\u3001\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306e\u7d04165\u6642\u9593\u306e\u534a\u6e1b\u671f\u306b\u5339\u6575\u3059\u308b\u90311\u56de\u306e\u6295\u4e0e\u30b9\u30b1\u30b8\u30e5\u30fc\u30eb\u3092\u5b9f\u73fe\u3057\u307e\u3059\u3002 <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u304c\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3088\u308a\u3082\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c\u304c\u9ad8\u3044\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>The most-cited mechanism is the GIP-receptor component. GIP-receptor activation contributes additional effects that GLP-1 alone doesn&#8217;t produce: enhanced adipocyte lipolysis under fasting conditions, modest increases in resting energy expenditure, and CNS effects in the dorsomedial hypothalamus distinct from arcuate-nucleus GLP-1 signalling. The combined dual signal produces an additive body-weight reduction beyond GLP-1 alone in head-to-head study models. <\/p>\n<h3>Does Tirzepatide cause side reported effects?<\/h3>\n<p>\u6700\u3082\u4e00\u8cab\u3057\u305f\u6240\u898b\u306f\u6d88\u5316\u5668\u7cfb\u306e\u3082\u306e\u3067\u3059\u3002\u5410\u304d\u6c17\u3001\u4e00\u904e\u6027\u306e\u98df\u6b32\u6291\u5236\u3001\u80c3\u5185\u5bb9\u6392\u51fa\u306e\u9045\u5ef6\u306f\u7528\u91cf\u4f9d\u5b58\u7684\u3067\u3042\u308a\u3001\u53d7\u5bb9\u4f53\u306e\u30bf\u30ad\u30d5\u30a3\u30e9\u30ad\u30b7\u30fc\u304c\u767a\u73fe\u3059\u308b\u306b\u3064\u308c\u3066\u3001\u901a\u5e384\uff5e8\u9031\u9593\u306e\u7d99\u7d9a\u6295\u4e0e\u3067\u8efd\u6e1b\u3059\u308b\u50be\u5411\u304c\u3042\u308a\u307e\u3059\u3002\u3042\u307e\u308a\u4e00\u822c\u7684\u3067\u306a\u3044\u6240\u898b\u3068\u3057\u3066\u306f\u3001\u80c6\u56a2\u904b\u52d5\u3078\u306e\u5f71\u97ff\u3084\u3001\uff08\u7532\u72b6\u817aC\u7d30\u80de\u611f\u53d7\u6027\u3092\u6709\u3059\u308b\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\uff09C\u7d30\u80de\u904e\u5f62\u6210\u304c\u542b\u307e\u308c\u307e\u3059\u3002\u5f8c\u8005\u306f\u7a2e\u7279\u7570\u7684\u306a\u30b7\u30b0\u30ca\u30eb\u3067\u3042\u308a\u3001\u9577\u671f\u306e\u81e8\u5e8a\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u306b\u304a\u3044\u3066\u30d2\u30c8\u3067\u306f\u78ba\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3002 <\/p>\n<h3>Can Tirzepatide and Semaglutide be compared in studies?<\/h3>\n<p>\u306f\u3044\u3001\u76f4\u63a5\u6bd4\u8f03\u306f\u30a4\u30f3\u30af\u30ec\u30c1\u30f3\u85ac\u7406\u5b66\u306b\u304a\u3044\u3066\u6700\u3082\u6d3b\u767a\u306b\u7814\u7a76\u3055\u308c\u3066\u3044\u308b\u30c6\u30fc\u30de\u306e\u4e00\u3064\u3067\u3059\u3002\u81e8\u5e8a\u8a66\u9a13SURPASS-2\u3067\u306f\u30012\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u30c1\u30eb\u30bc\u30d1\u30c1\u30c915mg\u3068\u30bb\u30de\u30b0\u30eb\u30c1\u30c91mg\u304c\u76f4\u63a5\u6bd4\u8f03\u3055\u308c\u307e\u3057\u305f\u3002\u524d\u81e8\u5e8a\u304a\u3088\u3073\u5897\u3048\u7d9a\u3051\u308b\u5b9f\u81e8\u5e8a\u30a8\u30d3\u30c7\u30f3\u30b9\u306b\u3088\u308a\u3001\u4f53\u91cd\u3001MASH\u3001\u5fc3\u8840\u7ba1\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u306b\u307e\u3067\u305d\u306e\u6bd4\u8f03\u306f\u62e1\u5927\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306f\u4f9d\u7136\u3068\u3057\u3066GLP-1\u306e\u6a19\u6e96\u7684\u306a\u6bd4\u8f03\u5bfe\u7167\u85ac\u3067\u3042\u308a\u3001\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u306f\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u6a19\u6e96\u7684\u306a\u6bd4\u8f03\u5bfe\u7167\u85ac\u3067\u3059\u3002 <\/p>\n<h3>How long does Tirzepatide take to show effects in preclinical studies?<\/h3>\n<p>Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1\u20132 weeks of weekly dosing and continue to accrue through 8\u201316 weeks. Maximum effect on body composition is typically observed after 16\u201324 weeks of continuous dosing in study models, mirroring the human-trial trajectory. <\/p>\n<h3>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3092\u56fd\u969b\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>Yes. MedsBase ships Tirzepatide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/semaglutide\/\"><strong>\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/strong><\/a> \u2014 Single GLP-1 agonist (Ozempic\/Wegovy\/Rybelsus active) \u2014 standard glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/ja\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 next-generation multi-axis metabolic support<\/li>\n<li><a href=\"\/ja\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<li><a href=\"\/ja\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded exercise-mimetic peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/ja\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Long-acting GHRH analog for growth-axis studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 \u9577\u6642\u9593\u4f5c\u7528\u578b\u30a4\u30f3\u30af\u30ec\u30c1\u30f3\u306e\u72b6\u6cc1\u3092\u6bd4\u8f03\u3057\u307e\u3059<\/strong><\/p>\n<p style=\"margin: 0;\">\u76f4\u63a5\u6bd4\u8f03\u30ac\u30a4\u30c9\u3092\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a href=\"https:\/\/medsbase.com\/ja\/retatrutide-vs-tirzepatide\/\"><strong>\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9 vs \u30c1\u30eb\u30bc\u30d1\u30c1\u30c9 \u2014 \u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8 vs \u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8<\/strong><\/a> KYC\uff08Know Your Customer\uff09 <a href=\"https:\/\/medsbase.com\/ja\/ozempic-vs-mounjaro\/\"><strong>Ozempic vs Mounjaro<\/strong><\/a>. \u53d7\u5bb9\u4f53\u85ac\u7406\u5b66\u3001\u914d\u5217\u5de5\u5b66\u3001\u534a\u6e1b\u671f\u3001\u7528\u91cf\u53cd\u5fdc\u6027\u3001\u306a\u3089\u3073\u306b\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9\u3092\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\uff08SURPASS-2\uff09\u304a\u3088\u3073\u30ec\u30bf\u30c8\u30eb\u30c1\u30c9\u306e\u30c8\u30ea\u30d7\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u7b2c2\u76f8\u8a66\u9a13\u7d50\u679c\u304b\u3089\u533a\u5225\u3059\u308b\u76f4\u63a5\u6bd4\u8f03\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u3092\u7db2\u7f85\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 GLP-1\/GIP\u30c7\u30e5\u30a2\u30eb\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac<br \/>\n\u2705 \u5358\u4e00\u30da\u30d7\u30c1\u30c9\u3067\u6700\u5927\u306e\u4f53\u91cd\u6e1b\u5c11\u52b9\u679c<br \/>\n\u2705 Supports glycaemic control<br \/>\n\u2705 \u8102\u80aa\u7d30\u80de\u3067\u306e\u8102\u80aa\u5206\u89e3\u3068\u30a8\u30cd\u30eb\u30ae\u30fc\u6d88\u8cbb<br \/>\n\u2705 \u90311\u56de\u6295\u4e0e\u30d7\u30ed\u30c8\u30b3\u30eb<\/p>\n<p><strong>\u30c1\u30eb\u30bc\u30d1\u30c1\u30c9<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70986,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,5418],"class_list":["post-70674","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-tirzepatide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70986"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70674"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70674"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70674"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}